* Prophylactic regimens resulted in low single-digit annualized bleeding rates
  * Median dosing interval was 14 days in the individualized interval
    prophylaxis arm during the last 6 months on study
  * Greater than 90% of bleeding episodes were controlled by a single injection
    of rFIXFc
  * No patients developed inhibitors to rFIXFc
  * The primary efficacy and safety objectives were met and Biogen Idec plans to
    submit a BLA to US FDA in first half 2013

Weston, Mass and Stockholm, Sweden - September 26, 2012 - Biogen Idec (NASDAQ:
BIIB) and Swedish Orphan Biovitrum (Sobi) (STO: SOBI) today announced positive
results from B-LONG, a clinical study that evaluated a new long-lasting clotting
factor candidate in people with hemophilia B. Hemophilia B is a rare inherited
disorder that impairs blood coagulation.

Top-line results from B-LONG, a global, multi-center, Phase 3 clinical study of
the companies' long-lasting recombinant Factor IX Fc fusion protein (rFIXFc),
showed that rFIXFc was effective in the control and prevention of bleeding,
routine prophylaxis, and perioperative management. Recombinant FIXFc was
generally well-tolerated. Additional analyses of the B-LONG study are ongoing
and the companies anticipate presenting further results at a future scientific

Biogen Idec plans to submit a Biologics License Application (BLA) to the U.S.
Food and Drug Administration (FDA) in the first half of 2013. Consistent with
guidelines published by the European Medicines Agency (EMA) that require a study
in children less than 12 years of age prior to filing, Biogen Idec and Sobi
expect to file a Marketing Authorization Application with the EMA upon
completion of the ongoing Kids B-LONG study.

"The results of the B-LONG study offer the potential for longer-lasting
protection from bleeding for patients with hemophilia B," said Glenn Pierce,
M.D., Ph.D., Senior Vice President of Global Medical Affairs and Chief Medical
Officer of Biogen Idec's hemophilia therapeutic area. "Currently, prophylactic
treatment of hemophilia B requires intravenous injections up to three times a
week, which makes the prospect of a longer-lasting Factor IX therapy very

"Our companies are pioneering the application of Fc fusion technology to extend
the half-life of clotting factors. Fc fusion technology utilizes a naturally-
occurring recycling pathway that has been successfully employed in other
therapeutic areas. This approach holds promise for combining more consistent
protection with fewer injections," said Geoffrey McDonough, M.D., Chief
Executive Officer of Sobi. "The B-LONG study results are highly encouraging and
support the potential use of this technology in hemophilia B."

Summary of Key Data from B-LONG
In the B-LONG study, 123 male patients aged 12 years and older were enrolled.
The B-LONG study had four treatment arms: weekly prophylaxis, individualized
interval prophylaxis, episodic treatment and perioperative management (Arms
1, 2, 3 and 4, respectively).

Overall, 93.5 percent of patients completed the study. Recombinant FIXFc was
generally well-tolerated. No inhibitors to rFIXFc were detected and no cases of
anaphylaxis were reported in any patients, all of whom switched from
commercially-available Factor IX products. One serious adverse event was
assessed to be possibly related to drug by the investigator. The patient
experienced obstructive uropathy in the setting of hematuria; he continued
rFIXFc treatment and the event resolved with medical management.

The most common adverse events (incidence of more than / equal 5 percent)
occurring outside of the perioperative management arm (i.e., Arms 1, 2 and 3,
but not Arm 4) were nasopharyngitis, influenza, arthralgia (joint pain), upper
respiratory infection, hypertension and headache.

The overall median annualized bleeding rates (including spontaneous and
traumatic bleeds) were 2.95 in the weekly prophylaxis arm, 1.38 in the
individualized interval prophylaxis arm, and 17.69 in the episodic treatment
arm. In the individualized interval prophylaxis arm, the median dosing interval
during the last 6 months on study was 14 days.

Control of bleeding was assessed in all patients who experienced a bleeding
episode during the study. Overall, 90.4 percent of bleeding episodes were
controlled by a single injection of rFIXFc.

Recombinant FIXFc was assessed in the perioperative management of 12 patients
undergoing 14 major surgical procedures. The treating physicians rated the
hemostatic efficacy of rFIXFc as excellent or good in 100 percent of these

B-LONG included a pharmacokinetic (PK) analysis of rFIXFc in all patients in the
study. In a protocol-defined subset of patients with extensive PK sampling, the
approximate terminal half-life of rFIXFc was 82 hours compared to 34 hours for
BeneFIX® [Coagulation Factor IX (Recombinant)].

About the B-LONG Study and the rFIXFc Program
B-LONG was a global, open-label, multi-center Phase 3 study that evaluated the
efficacy, safety and pharmacokinetics of intravenously-injected rFIXFc. The
study was designed to evaluate rFIXFc in the control and prevention of bleeding,
routine prophylaxis and perioperative management in patients with hemophilia B.
B-LONG involved 50 hemophilia treatment centers in 17 countries on 6 continents,
and is the largest registrational study conducted in hemophilia B.

The B-LONG study had four treatment arms. In Arm 1 (weekly prophylaxis; n=63),
patients were treated weekly with a starting dose of 50 IU/kg, which was
adjusted to maintain trough factor levels sufficient to prevent bleeding. In Arm
2 (individualized interval prophylaxis; n=29), patients were treated with 100
IU/kg, at an initial interval of 10 days, which was subsequently individualized
to maintain trough factor levels sufficient to prevent bleeding.  In Arm 3
(episodic treatment; n=27), patients received rFIXFc episodic treatment as
needed for bleeding. In Arm 4 (perioperative management; n=12 patients), rFIXFc
was evaluated in the surgical setting; 8 patients in the surgery arm were also
enrolled in other treatment arms.

The primary efficacy and safety measures were the annualized bleeding rate and
the incidence of adverse events and inhibitor development in patients studied
for up to 77 weeks. Secondary endpoints included response to treatment of
bleeding episodes and the pharmacokinetics of rFIXFc versus BeneFIX®.

Ongoing clinical studies of rFIXFc include the Kids B-LONG and the B-YOND
studies. Kids B-LONG is a Phase 3, open-label study in previously treated
children with hemophilia B under age 12, which is actively recruiting patients.
B-YOND is a long-term open-label extension study for patients who completed the
B-LONG study or who complete the Kids B-LONG study.

About the Fc Fusion Technology Platform
Recombinant FIXFc is a clotting factor developed using Biogen Idec's novel and
proprietary monomeric Fc fusion technology, which makes use of a natural pathway
to recycle rFIXFc in circulation and enable it to remain in the body longer.
With this technology, rFIXFc is designed to provide long-lasting protection from
bleeding and reduce the treatment burden associated with hemophilia B, which
currently requires more than 100 injections annually for prophylaxis with
commercially-available Factor IX products. Fc fusion technology is used in seven
FDA-approved products for the long-term treatment of chronic diseases including
rheumatoid arthritis, psoriasis and platelet disorders.

Using the same Fc fusion technology, Biogen Idec and Sobi are also developing a
long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) for the
control and prevention of bleeding episodes and routine prophylaxis in
hemophilia A. Top-line results from the A-LONG study are expected later this
year. For more information on Biogen Idec's hemophilia research programs, visit

About Hemophilia B
Hemophilia B is a rare, inherited disorder in which the ability of a person's
blood to clot is impaired. Hemophilia B occurs in about one in 25,000 male
births annually and is caused by having substantially reduced or no Factor IX
activity, which is needed for normal blood clotting. People with hemophilia B
therefore need injections of Factor IX to restore the coagulation process and
prevent frequent bleeds that could otherwise lead to pain, irreversible joint
damage and life-threatening hemorrhages. The Medical and Scientific Advisory
Council of the National Hemophilia Foundation recommends prophylaxis as the
optimal therapy for people with severe hemophilia B. Currently, prophylaxis in
hemophilia B typically requires injections up to three times per week to
maintain a sufficient circulating level of clotting factor.

About the Biogen Idec and Sobi Collaboration
Biogen Idec and Sobi are partners in the development and commercialization of
rFIXFc and rFVIIIFc. Biogen Idec leads development, has manufacturing rights,
and has commercialization rights in North America and all other regions
excluding the Sobi territory. Sobi has the right to opt in to assume final
development and commercialization in Europe including Russia, the Middle East
and Northern Africa.

 Biogen Idec Media Contact:              Swedish Orphan Biovitrum:
 Jim Baker                               Åsa Stenqvist
 Senior Manager, Public Affairs          Head of Communications and Investor
 +1-781-464-3260                         Relations
                                         +46 8 697 21 88
 Biogen Idec Investor Relations Contact:
 Kia Khaleghpour
 Director, Investor Relations

About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and
delivers to patients worldwide innovative therapies for the treatment of
neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in
1978, Biogen Idec is the world's oldest independent biotechnology company.
Patients worldwide benefit from its leading multiple sclerosis therapies, and
the company generates more than $5 billion in annual revenues. For product
labeling, press releases and additional information about the company, please

About Sobi
Sobi is an international healthcare company dedicated to bringing innovative
therapies and services to improve the lives of rare disease patients. The
product portfolio is primarily focused on inflammation and genetic diseases,
with three late stage biological development projects within hemophilia and
neonatology. Sobi also markets more than 40 products for companies in the
specialty and rare disease space. In 2011, Sobi had revenues of SEK 1.9 billion
and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at

Safe Harbor
This press release contains forward-looking statements, including statements
about the development and commercialization of long-lasting hemophilia therapies
and regulatory filings. These statements may be identified by words such as
"believe," "expect," "may," "plan," "will" and similar expressions, and are
based on the companies' current beliefs and expectations. Drug development and
commercialization involve a high degree of risk. Factors which could cause
actual results to differ materially from the companies' current expectations
include the risk that unexpected concerns may arise from additional data or
analysis, regulatory authorities may require additional information or further
studies, or may fail to approve our drug candidates, or the companies may
encounter other unexpected hurdles. For more detailed information on the risks
and uncertainties associated with Biogen Idec's drug development and
commercialization activities, please review the Risk Factors section of Biogen
Idec's most recent annual or quarterly report filed with the Securities and
Exchange Commission. Any forward-looking statements speak only as of the date of
this press release and the companies assume no obligation to update any forward-
looking statements, whether as a result of new information, future events or

The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information was
released for public distribution on September 26, 2012 at 1:30 p.m. CET.



Documents & Links